What are the indications for Vebreltinib?

Vebreltinib is a new domestically developed targeted drug that mainly acts on the mesenchymal-epithelial transformation factor (MET) signaling pathway. This pathway plays a key role in the occurrence and development of various tumors. In particular, patients carrying specific gene mutations or fusions have limited response to traditional treatments and therefore are in urgent need of effective molecular targeted drugs. The emergence of buricitinib provides new treatment options for these patients.

Currently, the primary indication for boricitinib is locally advanced or metastatic non-small cell lung cancer (NSCLC), especially patients with MET exon 14 skipping. Although the proportion of such mutations in lung cancer is not high, it has a significant impact on disease progression and prognosis. Traditional chemotherapy or immunotherapy has limited efficacy in this type of patients. However, bricitinib fundamentally blocks the proliferation and survival of tumor cells by precisely inhibiting MET pathway signaling, bringing a breakthrough treatment solution to this niche patient group.

In addition to lung cancer, another important indication for boricitinib is central nervous system tumors, especially IDH-mutant astrocytomas (WHO grade IV) with the PTPRZ1-MET fusion gene, as well as some glioblastomas with a history of low-grade disease. Due to the special location and strong invasiveness of this type of tumor, the efficacy of traditional surgery, radiotherapy and chemotherapy is often limited, and the recurrence rate is extremely high. By targeting the MET fusion signal, bripretinib is expected to delay tumor progression and improve patients' quality of life.

It is worth emphasizing that the research and development background of briboritinib is highly in line with the international frontier, and its indication selection is not only based on the needs of domestic patients, but also consistent with the global research trend onMET-related tumors. This means that boricitinib may be clinically explored in more solid tumor areas in the future, including gastric cancer, liver cancer, some colorectal cancers and other diseases related to abnormal activation of MET.

Reference materials:https://www.asymbio.com.cn/